Ambrose Healthcare Exercise Option on VAL 401 Out License Agreement for £16 Million plus Royalties
Avacta Group PLC (AIM:AVCT) New Response in Phase 1b Trial
New Response in the FAP-Dox (AVA6000) Phase 1b Trial
SkinBioTherapeutics (AIM:SBTX) Superdrug agreement, Placing & Retail Offer
SkinBioTherapeutics signs exclusive commercial agreement with Superdrug for AxisBiotix™ products in the UK Placing and Subscription to raise £4.1m to support Superdrug agreement; Proposed Retail Offer to existing shareholders of
Celadon Pharmaceuticals (AIM:CEL) New Committed Credit Facility
Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on the research, cultivation, manufacturing, and sale of breakthrough cannabis-based medicines, announces that further to the 6 June 2025 announcement, it
OptiBiotix Health – SlimBiome® study in European Journal of Nutrition
New SlimBiome® study published in European Journal of Nutrition
Totally PLC (AIM:TLY) Intention to Appoint Administrators and Share Suspension
Totally PLC has announced its intention to appoint administrators and has suspended trading in its shares on AIM with immediate effect.
Avacta Group PLC (AIM:AVCT) Preliminary Full Year 2024 Results
Preliminary Results for the Year Ended December 31, 2024
Avacta Group PLC (AIM:AVCT) Avacta Change in Prelim Date Part 2
Update on timing of preliminary results announcement
Hemogenyx Pharma Plc (LON:HEMO) Second Patient Passes Initial Safety Tests
Second Patient Treated with HG-CT-1 CAR-T Therapy Successfully Passes Initial Safety Evaluation
hVIVO PLC (AIM:HVO) Director/PDMR Shareholding
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that on Friday 30 May 2025, Yamin ‘Mo’ Khan, Chief
Genedrive PLC (AIM:GDR) received European regulatory approval
Genedrive wins EU approval for rapid genetic test aimed at stroke and heart attack care
hVIVO PLC (AIM:HVO) Trading update
hVIVO plc (AIM: HVO), a full-service Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that it has received notification of a significant human challenge